Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL - Episode 4

Guiding Patients Through CAR T: Key Discussion Points

,

Experts discuss key points to share with patients when counseling or first introducing chimeric antigen receptor T-cell therapy (CAR T), focusing on expectations, potential adverse effects, and the treatment process

EP. 1: CAR-T in Second-Line DLBCL: When and for Whom?
EP. 2: Real-World Data and CAR T Selection in Second-Line LBCL: Key Insights From ASH 2024
EP. 3: CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection
Now Viewing
EP. 4: Guiding Patients Through CAR T: Key Discussion Points
EP. 5: Future Directions for CAR T-Cell Therapy in LBCL: What’s Next?
EP. 6: Optimizing CAR T for R/R CLL: Timing and Treatment Sequencing Strategies
EP. 7: Novel Combination Therapies in First-Line CLL: Potential Impact of Treatment Sequencing
EP. 8: CAR T in CLL: Data Highlights and Long-Term Outcomes From ASH 2024
EP. 9: Overcoming Barriers and Improving CAR T Care in Academic and Community Settings
EP. 10: Key Takeaways: CAR T in Real-World Clinical Practice

Video content above is prompted by the following:

  • What do you share with your patients when counseling or first introducing CAR T-cell therapy?

Related Content:

Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL Video SeriesInsights
Key Messages From the Breast Cancer ADC Data Set and Closing Remarks
Treatment Duration, Maintenance Concepts, and Development of New ADC Targets in Breast
Combination Approaches With ADCs and Emerging Clinical Strategies in Breast Cancer